Fetal Anomaly Screening for Detection of Congenital Heart Defects
- *Corresponding Author:
- Yogen Singh
Department of Neonatology and Paediatric Cardiology
Cambridge University Hospitals, United Kingdom
Tel: +44 1223 216240
Fax: +44 1223 586794
E-mail: [email protected]
Received March 14, 2016; Accepted April 19, 2016; Published April 22, 2016
Citation: Mbamalu ON, Antunes E, Silosini N, Samsodien H, Syce J (2016) HPLC Determination of Selected Flavonoid Glycosides and their Corresponding Aglycones in Sutherlandia frutescens Materials. Med Aromat Plants 5:246. doi:10.4172/2167-0412.1000246
Copyright: © 2016 Mbamalu ON, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Congenital heart defects remain the most common congenital malformation in live births and are the leading cause of infant mortality in the developed world. Major developments in the management over the last decade have led to significant improvements in survival of infants with congenital heart defects. Early diagnosis and timely appropriate management of critical and serious CHDs is essential to improve outcome. Feat anomaly screening is being used detect the critical and significant congenital heart defects prenatally between 18+0 weeks and 20+6 weeks of pregnancy. This helps professional and parents in critical decision making regarding the pregnancy, planning for delivery and preparing the parents for the anticipated problems. Prenatal diagnosis of critical congenital heart conditions has shown to improve the outcome in infants with critical congenital heart defects.